logo
Time to act on Indigenous health inequities: ending discrimination based on place of residence!

Time to act on Indigenous health inequities: ending discrimination based on place of residence!

Yahoo4 days ago

National Forum on Urban Indigenous Health Governance in Care, Health Services and Healing
MONTRÉAL, May 29, 2025 (GLOBE NEWSWIRE) -- During the National Forum on Urban Indigenous Health Governance in Care, Health Services and Healing, the Native Friendship Centres from across the country are making an urgent appeal to the Government of Canada. These Friendship Centres, from 9 provinces and 3 territories, are calling for an end to the glaring inequity in health and social services for urban Indigenous people living outside their home communities. Their health and wellness indicators reveal a significant gap with the rest of the population, and it's time that this be addressed.
With their Statement for More Inclusive Indigenous Health, the Friendship Centres are calling on the federal government to immediately commit to the following:
Recognize the distinct needs of all indigenous populations, regardless of where they live;
Unreservedly recognize the expertise of the Friendship Centres in providing front-line services for Indigenous people living in urban areas; and
Provide stable, flexible and permanent funding to the Friendship Centres, to enable them to develop or enhance health and social services within their infrastructures.
Urban Indigenous people continue to be marginalized and face many cultural, linguistic and social barriers in a health care system that is designed for the non-Indigenous reality. Public policy currently favours Indigenous people living on reserves, while the majority (59.4%1) of First Nations members live permanently in cities. This geographical favouritism creates a huge imbalance every day.
Friendship Centres: On the front line
Many Friendship Centres have taken the initiative to open their own community health clinics tailored to the needs of Indigenous people. They take action despite there being little to no federal funding earmarked for health services for urban Indigenous populations, in addition to a lack of official recognition. Urban Indigenous people's specific realities raise unique challenges that Friendship Centres are best equipped to address, but doing so requires formal recognition as well as a significant financial investment.
The importance of cultural safety
In cities, Indigenous people face many challenges in accessing appropriate healthcare. Public health care personnel have a limited understanding of Indigenous realities, which can lead to snap judgments and discriminatory attitudes. It's not enough to acknowledge the existence of systemic racism in public services; concrete action must be taken to eliminate it, including by investing in indigenous health clinics that meet the specific needs of urban Indigenous and promote equitable access to care.
Quote
'Ignoring the health needs of urban Indigenous people perpetuates historical injustices. By improving their physical and mental health, we help establish a healthier population that learns, works, creates, provides care and passes on knowledge.'
Jocelyn W. Formsma, Chief Executive Officer of the National Association of Friendship Centres
About the Regroupement des centres d'amitié autochtones du Québec (RCAAQ)
The RCAAQ is a network of 11 Friendship Centres in 14 Quebec cities, offering Indigenous people culturally relevant and safe services that contribute to the harmony and reconciliation between peoples in Quebec cities. The Friendship Centres are the largest urban service infrastructure for Indigenous people, offering a range of integrated services in a variety of sectors, including health, social services, justice, social inclusion, education, employability, early childhood and youth.
About the National Association of Friendship Centres (NAFC)
The NAFC represents over 100 local Friendship Centres and provincial/territorial associations across the country (excluding Prince Edward Island). Friendship Centres are urban Indigenous community hubs that offer a wide range of programs and services to First Nations, Inuit and Métis people living in urban, rural and northern communities. Collectively, Friendship Centres form the largest urban Indigenous service delivery network in Canada.
Information
Myrian MarotteRCAAQmyrian.marotte@rcaaq.info514-913-4478
1 Statistics Canada, 2021.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Navigating the Future of Anti-Aging - Emerging Market Structures and Strategies for Longevity Breakthroughs
Navigating the Future of Anti-Aging - Emerging Market Structures and Strategies for Longevity Breakthroughs

Yahoo

time43 minutes ago

  • Yahoo

Navigating the Future of Anti-Aging - Emerging Market Structures and Strategies for Longevity Breakthroughs

The Complementary & Alternative Medicine For Anti Aging & Longevity Market is thriving due to rising global life expectancy and healthspan focus. Key opportunities include personalized, integrative therapies, botanical and digital health innovations, strategic global alliances, and addressing demographic dynamics and regulatory shifts. Complementary & Alternative Medicine For Anti Aging & Longevity Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Complementary & Alternative Medicine For Anti Aging & Longevity Market by Product Type, Distribution Channel, End User, Therapy Type, Age Group, Gender - Global Forecast to 2030" has been added to market for Complementary & Alternative Medicine for Anti-Aging & Longevity is experiencing robust growth, marking a transition from USD 51.87 billion in 2024 to a projected USD 146.29 billion by 2030, at an impressive CAGR of 18.86%. As consumer interest in extending life expectancy and improving health-span reaches new heights, the demand for innovative anti-aging solutions is expanding. Advances in molecular biology and a rising awareness of preventive health strategies are propelling individuals towards modalities that promise enhanced vitality. The market research report provides insights into key drivers transforming this sector, equipping decision-makers with the knowledge needed to navigate this evolving landscape strategically. Understanding the Surge of Anti-Aging and Longevity Modalities Significant transformations are emerging as the sector shifts from niche products to comprehensive wellness ecosystems. Regulatory frameworks are evolving to support new ingredients and personalized therapies, enhancing market entry. Technological advancements in biomarker analytics are delivering insights for precision nutraceuticals, personalized botanicals, and digital health platforms, enabling unique consumer engagements. This section maps emerging research, regulatory changes, and market trends, offering strategic guidance for stakeholders aiming to capitalize on growth inflection points within the decade. Pivotal Transformations Reshaping Anti-Aging Solutions The anti-aging landscape is evolving towards integration, with regulatory adaptations accommodating cutting-edge innovations. Technological advances in omics platforms foster the rise of personalized nutraceuticals. At the same time, e-commerce and telehealth are democratizing access to longevity expertise. Strategic alliances are reshaping research pathways, facilitating faster market entry for breakthrough therapies. This transformation highlights the need for stakeholders to focus on agility and collaboration to stay competitive. Tariff Realignments Recasting Market Dynamics in 2025 The introduction of new tariffs in 2025 has influenced cost structures across supply chains, compelling manufacturers to reevaluate sourcing strategies. These tariffs have prompted local cultivation initiatives and geographic manufacturing shifts to maintain cost-effectiveness and quality. Companies must adjust their approaches, balancing ingredient efficacy with cost-efficiency to navigate the tariff landscape effectively. Key Takeaways from This Report This report offers insights into consumer behaviors, technological advancements, and strategic collaborations that shape market dynamics. Decision-makers gain tools for strategic planning, competitive advantage, and risk mitigation, ensuring they can align investments with emerging trends. The detailed segmentation analysis reveals pathways for tailored propositions to maximize audience engagement and growth potential. Deep-Dive into Market Segmentation Revealing Consumer Behaviors Understanding consumer preferences is crucial for sustaining category performance. Botanical extracts, dietary supplements, herbal medicines, and nutraceuticals each exhibit unique market demands. Distribution channels like direct sales and online retail have expanded consumer access, while end-user analysis highlights diverse engagement patterns among fitness centers, healthcare providers, and wellness centers. Demographic insights further refine understanding, highlighting opportunities for tailored marketing strategies. Regional Nuances Driving Growth Across Continents Geographical variations significantly influence growth trajectories. In the Americas, regulatory acceptance and infrastructure investment fuel market expansion. Europe's emphasis on quality benchmarks fosters opportunities, while Asia-Pacific markets blend traditional medicine with biotech innovation. Understanding these regional dynamics is vital for crafting effective market entry and expansion strategies. Competitive Landscape Spotlight on Leading Innovators The competitive landscape is characterized by conglomerates and specialized pioneers, each deploying unique strategies to capture market share. Strategic acquisitions, alliances, and technological advancements in delivery systems are reshaping industry boundaries. Emerging players focus on novel solutions that challenge established paradigms, drawing venture capital and driving innovation across the sector. Strategic Imperatives for Industry Front-Runners To foster sustained growth, industry leaders must balance personalization and scalability through advanced analytics and real-world evidence. Diversified sourcing optimizes supply chains against tariff volatility, enhancing resilience. Cross-sector collaborations and thought leadership will expand market reach and cement authority within the anti-aging domain. Rigorous Framework Underpinning Research Integrity This report utilizes comprehensive primary and secondary research methodologies to ensure credibility and relevance. Structured interviews and surveys combined with a review of peer-reviewed publications provide a holistic view of market dynamics. Advanced analytical frameworks offer strategic context, reinforcing the report's actionable intelligence. Synthesizing Insights to Chart the Path Forward The integration of botanical heritage, nutraceutical advancements, and digital health marks a new era for anti-aging solutions. As tariffs, consumer trends, and regional idiosyncrasies reshape market dynamics, stakeholders must adopt a strategic, data-driven perspective to capitalize on emerging opportunities and secure a competitive edge. Key Attributes: Report Attribute Details No. of Pages 190 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $61.93 Billion Forecasted Market Value (USD) by 2030 $146.29 Billion Compound Annual Growth Rate 18.8% Regions Covered Global Key Topics Covered: 1. Preface2. Research Methodology3. Executive Summary4. Market Overview4.1. Introduction4.2. Market Sizing & Forecasting5. Market Dynamics6. Market Insights6.1. Porter's Five Forces Analysis6.2. PESTLE Analysis7. Cumulative Impact of United States Tariffs 20258. Complementary & Alternative Medicine For Anti Aging & Longevity Market, by Product Type8.1. Introduction8.2. Botanical Extract8.2.1. Aloe Vera8.2.2. Gotu Kola8.3. Dietary Supplement8.3.1. Amino Acids8.3.2. Minerals8.3.3. Probiotics8.3.4. Vitamins8.4. Herbal Medicine8.4.1. Ginseng8.4.2. Green Tea8.4.3. Resveratrol8.4.4. Turmeric8.5. Nutraceutical8.5.1. Coenzyme Q108.5.2. Collagen8.5.3. Omega-39. Complementary & Alternative Medicine For Anti Aging & Longevity Market, by Distribution Channel9.1. Introduction9.2. Direct Sales9.3. Hospital Clinics9.4. Online Retail9.5. Pharmacy9.6. Specialty Store10. Complementary & Alternative Medicine For Anti Aging & Longevity Market, by End User10.1. Introduction10.2. Fitness Center10.3. Healthcare Provider10.4. Individual Consumer10.5. Wellness Center11. Complementary & Alternative Medicine For Anti Aging & Longevity Market, by Therapy Type11.1. Introduction11.2. Energy Therapy11.3. Manual Therapy11.4. Mind Body Therapy11.5. Nutritional Therapy11.5.1. Caloric Restriction11.5.2. Dietary Counseling11.5.3. Fasting11.6. Traditional Alternative System12. Complementary & Alternative Medicine For Anti Aging & Longevity Market, by Age Group12.1. Introduction12.2. 18 to 35 Years12.3. 36 to 50 Years12.4. 51 Years and Above13. Complementary & Alternative Medicine For Anti Aging & Longevity Market, by Gender13.1. Introduction13.2. Female13.3. Male14. Americas Complementary & Alternative Medicine For Anti Aging & Longevity Market15. Europe, Middle East & Africa Complementary & Alternative Medicine For Anti Aging & Longevity Market16. Asia-Pacific Complementary & Alternative Medicine For Anti Aging & Longevity Market17. Competitive Landscape17.1. Market Share Analysis, 202417.2. FPNV Positioning Matrix, 202417.3. Competitive Analysis Herbalife Nutrition Ltd. Amway Corp. The Bountiful Company GNC Holdings Pharmavite USANA Health Sciences, Inc. Glanbia Plc H&H International Holdings Ltd Nature's Sunshine Products, Inc. Jamieson Wellness Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Complementary & Alternative Medicine For Anti Aging & Longevity Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030
Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030

Yahoo

timean hour ago

  • Yahoo

Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030

Antibody discovery, crucial for developing targeted therapies in fields like oncology and autoimmune diseases, is evolving with innovations like phage display and AI-driven design. The market is booming across North America, Europe, and Asia-Pacific, driven by personalized medicine and rapid advancements in antibody discovery technologies. Antibody Discovery Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Antibody Discovery - Global Strategic Business Report" has been added to global market for Antibody Discovery was valued at US$1.9 Billion in 2024 and is projected to reach US$3.3 Billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Antibody Discovery market. Why Is Antibody Discovery at the Forefront of Next-Generation Therapeutic Development?Antibody discovery is emerging as a cornerstone of modern drug development, driven by the escalating demand for targeted therapies across oncology, autoimmune disorders, infectious diseases, and rare conditions. Monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs) are transforming clinical outcomes through their high specificity, tunable pharmacokinetics, and ability to engage or inhibit precise molecular targets. The discovery phase - encompassing target identification, antibody generation, screening, and lead optimization - is critical to ensuring downstream therapeutic efficacy, safety, and commercial viability. As biopharmaceutical pipelines increasingly prioritize biologics over small molecules, antibody discovery is becoming an indispensable gateway to innovation.A significant driver of this trend is the surge in demand for personalized medicine and immunotherapy, where antibody-based therapeutics are used to modulate immune response, block disease-associated pathways, or deliver cytotoxic payloads directly to tumor cells. The urgency created by the COVID-19 pandemic further underscored the importance of rapid antibody discovery, as neutralizing antibodies became pivotal in the therapeutic and diagnostic response to SARS-CoV-2. Global interest in therapeutic antibodies is prompting pharmaceutical and biotech firms to accelerate discovery programs using faster, more predictive, and less immunogenic methods. As the market shifts from traditional hybridoma techniques to humanized platforms and next-gen in silico approaches, antibody discovery is positioned at the heart of biopharma R&D strategies Are Technological Innovations Accelerating Discovery Timelines and Improving Lead Quality?Cutting-edge technologies are reshaping every stage of the antibody discovery process, enabling faster identification of high-affinity, developable antibodies with favorable safety and manufacturability profiles. Phage display and yeast display platforms have largely replaced traditional hybridoma-based generation, offering vast diversity libraries and rapid selection capabilities. More recently, microfluidics, single B-cell screening, and high-throughput sequencing have revolutionized early-stage discovery by capturing naturally occurring antibody repertoires from immunized animals or convalescent human donors. These tools enable the isolation of rare, highly potent antibodies that would otherwise go undetected through conventional biology and AI-driven design are also transforming the discovery pipeline by predicting binding affinity, stability, immunogenicity, and epitope specificity in silico. Machine learning algorithms are being trained on large antibody datasets to accelerate lead optimization, reduce experimental trial-and-error, and improve success rates in later development phases. Humanization techniques - ranging from chimerization to full deimmunization - are being refined to enhance safety and reduce rejection risk. Additionally, CRISPR/Cas9 and transgenic animal models are being leveraged to generate fully human antibodies with precise specificity. These technology integrations are enabling rapid, scalable, and cost-efficient antibody discovery workflows that meet the high standards of regulatory and therapeutic Is Market Demand Rising and Which Therapeutic Areas Are Driving Discovery Investment?Market demand for antibody discovery services and platforms is rising sharply across North America, Europe, and Asia-Pacific, where biopharma companies, academic labs, and contract research organizations (CROs) are intensifying efforts to expand antibody-based pipelines. The U.S. leads in therapeutic antibody development, backed by significant biotech investment, advanced research infrastructure, and regulatory support for expedited biologic approvals. Europe, particularly Germany, Switzerland, and the U.K., is seeing strong growth in CRO-based discovery partnerships and academic spinouts. Meanwhile, Asia-Pacific - especially China, South Korea, and Japan - is becoming a major hub for antibody innovation, fueled by state-backed biotech programs, growing clinical trial activity, and rapid commercialization remains the largest and fastest-growing therapeutic segment for antibody discovery, accounting for the majority of pipeline activity in monoclonal and bispecific antibodies. Immuno-oncology applications, such as checkpoint inhibitors and T-cell engagers, are expanding rapidly with significant investment in PD-1/PD-L1, CTLA-4, CD3, and CD20 targets. Autoimmune and inflammatory diseases - including rheumatoid arthritis, psoriasis, and Crohn's disease - also represent major discovery areas, with antibody candidates aimed at cytokines and immune receptors such as IL-6, TNF-alpha, and IL-17. Infectious disease research continues to drive antibody discovery in the wake of COVID-19, with new programs targeting HIV, RSV, and influenza. Rare and neurological diseases, including ALS, Alzheimer's, and neuromyelitis optica, are emerging as high-value niches for precision antibody therapies. These diverse and expanding indications are propelling sustained investment and innovation in antibody discovery workflows across Is Fueling the Growth of the Global Antibody Discovery Market?The growth in the antibody discovery market is driven by several factors, including the rising prevalence of chronic and rare diseases, expansion of biologics pipelines, and breakthroughs in molecular screening and AI-assisted drug design. A central driver is the therapeutic success of antibodies already in the market - such as trastuzumab, adalimumab, and pembrolizumab - which continue to demonstrate the clinical and commercial potential of antibody-based drugs. The robust deal activity between pharmaceutical giants and antibody discovery specialists is further catalyzing growth, as companies seek early access to differentiated platforms and promising outsourcing by biotech startups and mid-sized firms is also fueling market demand for discovery-as-a-service models, where CROs and specialized technology vendors provide end-to-end discovery capabilities from antigen design to humanized lead delivery. Advances in automation, sequencing, and data analytics are lowering the cost per discovery while improving success predictability, making antibody R&D more accessible to smaller players. Moreover, government and institutional funding for pandemic preparedness, cancer immunotherapy, and biosimilar development are boosting both public and private sector involvement. As antibody therapeutics become increasingly central to precision medicine and immune modulation, a crucial question emerges - can antibody discovery platforms keep pace with the clinical complexity and specificity required for next-generation, globally accessible biologic treatments?Report ScopeThe report analyzes the Antibody Discovery market, presented in terms of market value (US$ Thousand). The analysis covers the key segments outlined Antibody Type (Monoclonal, Polyclonal, Other Antibody Types) Service (Phage Display, Hybridoma, Other Services) End-Use (Pharmaceutical & Biotechnology Companies, Research Laboratories, Other End-Uses) Key Insights: Market Growth: Understand the significant growth trajectory of the Monoclonal Antibody segment, which is expected to reach US$2 Billion by 2030 with a CAGR of a 9.3%. The Polyclonal Antibody segment is also set to grow at 10.9% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $500.0 Million in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $530.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam, AbCellera Biologics, Ablexis, Adimab, Akeso Biopharma and more. Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments and incorporates forward-looking insights into the market analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities. Key Attributes: Report Attribute Details No. of Pages 224 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.9 Billion Forecasted Market Value (USD) by 2030 $3.3 Billion Compound Annual Growth Rate 9.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW World Market Trajectories Antibody Discovery - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Demand for Precision Biologics Spurs Innovation Across the Antibody Discovery Landscape AI-Driven Screening Platforms Shorten Discovery Timelines for Therapeutic Antibodies Next-Generation Sequencing and Single-Cell Tools Redefine Antibody Target Identification CRO Partnerships Accelerate Outsourced Antibody Discovery Among Biopharma Firms Oncology and Autoimmune Therapies Dominate the Clinical Focus of Antibody Discovery Pipelines Transgenic Animal Models Expand the Scope of Novel Antibody Generation Bispecific and Monoclonal Advances Unlock Complex Disease Targeting in Antibody Discovery Data Integration Across Platforms Enhances Efficiency in Antibody Optimization Collaborations with Academia Infuse Innovation into Antibody Discovery Frameworks Expiry of Biologic Patents Opens New Pathways for Biosimilar Antibody Development Regulatory Support for First-in-Class Biologics Encourages Bold Innovation in Discovery End-to-End Platform Integration Strengthens the Commercial Value Chain in Antibody Discovery FOCUS ON SELECT PLAYERSSome of the 41 companies featured in this Antibody Discovery market report include: Abcam AbCellera Biologics Inc. Ablexis Adimab Akeso Biopharma Biocytogen Pharmaceuticals Co., Ltd. Bruker Corporation Charles River Laboratories ChemPartner Creative Biolabs Danaher Corporation Eurofins Scientific Evotec SE FairJourney Biologics Genmab GenScript Biotech Corporation Harbour BioMed Icosagen AS ImmunoPrecise Antibodies Ltd. Isogenica Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Discovery Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development

Yahoo

timean hour ago

  • Yahoo

Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development

MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company's Oxford, UK site. With more than 35 years in the pharmaceutical industry, Louise brings extensive and highly relevant experience to Aravax having previously made key contributions to the approval of Palforzia® - the first and only FDA approved oral immunotherapy (OIT) to treat peanut allergy. Louise has held prior roles as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics AG and Alladapt Immunotherapeutics and was Head of Pharma R&D at Nestle Health Science/Aimmune Therapeutics (acquired by Nestle Health Science in 2020) where she had broad responsibilities for global regulatory affairs across pharma products in food allergy, gastrointestinal and metabolic disorders. Whilst at Aimmune, Louise was responsible for activities supporting the development and marketing approvals for Palforzia® in the US, EU, UK and Switzerland. Louise's early career included senior positions at Abbott Laboratories, Auxilium Pharmaceuticals, Intermune and Circassia. Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London. Louise Peacock, Chief Regulatory and Quality Officer of Aravax, said, 'Despite recent advances, food allergy remains an ever-growing and life-threatening problem around the world and there is a critical need for better therapies. Having followed Aravax's developments, I am convinced that PVX108 has the potential to be a life-changing alternative for patients with peanut allergy. I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 and other products.' Dr Pascal Hickey, CEO of Aravax, said, 'Louise's experience in regulatory affairs in the field of food allergy is unique. It spans all the major regulatory bodies and multiple programs including the successful approval of Palforzia®. We are enormously excited that she is joining the Aravax team.' About Aravax Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches. Aravax's proprietary platform generates engineered peptides that precisely retrain the immune system and restore the body's ability to safely tolerate food allergens, without putting patients at risk of treatment-induced acute allergic reactions, including anaphylaxis. The lead product, PVX108, is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. Aravax is also developing a pipeline of products tackling additional significant food allergy indications. Aravax is an international company headquartered in Melbourne, Australia with a subsidiary in Oxford, UK and operations in USA and Europe. Aravax's investors include leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper. For more information visit: For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585Chris Gardner, E: Chris@ M: +44 (0)7956 031077Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store